<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617382</url>
  </required_header>
  <id_info>
    <org_study_id>S-54350</org_study_id>
    <nct_id>NCT01617382</nct_id>
  </id_info>
  <brief_title>Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed</brief_title>
  <acronym>HIPEC</acronym>
  <official_title>Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to register the follow-up data of patients who, because of a
      peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To register the follow-up data of patients who, because of a peritoneal surface malignancy,
      will undergo cytoreductive surgery and HIPEC. In this surgical intervention, the abdominal
      cavity is macroscopically cleared of tumor, by removing all visible tumor nodules, and is
      subsequently rinsed with hyperthermic (heated) chemotherapy, aiming to destroy all residual
      invisible tumor cells that might have stayed behind after the debulking.

      The eventual aim of this procedure is to improve the prognosis/survival of patients with
      malignancies localized on the peritoneal surface.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.</measure>
    <time_frame>Follow-up over a time period of at least 5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <condition>Pseudomyxoma Peritonei</condition>
  <condition>Peritoneal Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Registry</arm_group_label>
    <description>Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma
        peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to
        undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with peritoneal carcinomatosis of colorectal origin, patients with
             pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma
             who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal
             surface malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André JL D'Hoore, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinics Gasthuisberg Department of Abdominal Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle B Terrasson</last_name>
    <phone>+32 16 340837</phone>
    <email>isabelle.terrasson@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Clinics Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle B Terrasson</last_name>
      <phone>+32 16 340837</phone>
      <email>isabelle.terrasson@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Daphne Hompes, MD</last_name>
      <phone>+32 16 341826</phone>
      <email>daphne.hompes@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>André JL D'HOORE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIPEC</keyword>
  <keyword>Hyperthermic (heated) chemotherapy after debulking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Pseudomyxoma Peritonei</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

